IL6 and metabolic syndrome: Tocilizumab, a humanized monoclonal antibody that targets both the soluble and membranous forms of interleukin-6 (IL-6) receptor, exacerbates dyslipidemia by blocking IL-6 signaling and inducing apolipoprotein expression in the liver [14].